Menu PROMETHEUS LABORATORIES Status: Historic In 2001, DLJMB participated in the recapitalization of Prometheus Laboratories, a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. The company focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. Headquarters: San Diego, CA www.prometheuslabs.com About Approach Team Portfolio News Contact Investor Login Avista Capital Holdings, LP 65 East 55th Street 18th Floor New York, NY 10022 info@avistacap.com 212-593-6900 © 2021 Avista Capital Partners. Terms Of Use Privacy Policy Nothing contained herein constitutes an offer to sell or a solicitation of an offer to purchase any investments or securities of any investment vehicles. Any such offer or solicitation shall be made only pursuant to a confidential offering memorandum relating to such vehicles, which will qualify in its entirety any information set forth herein. The specific companies identified and described above do not represent all of the companies purchased or sold by Avista. No assumption should be made that investments in these companies were or will be profitable.

Menu EDDIE ZHAO ASSOCIATE Eddie Zhao is an Associate at Avista Capital Partners. Mr. Zhao joined Avista Capital Partners in 2019. Prior to joining Avista, Mr. Zhao worked as an analyst at Wells Fargo Securities in the Financial Sponsors Group. Mr. Zhao received a B.S.E. in Biomedical Engineering and a B.S. in Economics with a minor in Mathematics from Duke University. About Approach Team Portfolio News Contact Investor Login Avista Capital Holdings, LP 65 East 55th Street 18th Floor New York, NY 10022 info@avistacap.com 212-593-6900 © 2021 Avista Capital Partners. Terms Of Use Privacy Policy Nothing contained herein constitutes an offer to sell or a solicitation of an offer to purchase any investments or securities of any investment vehicles. Any such offer or solicitation shall be made only pursuant to a confidential offering memorandum relating to such vehicles, which will qualify in its entirety any information set forth herein. The specific companies identified and described above do not represent all of the companies purchased or sold by Avista. No assumption should be made that investments in these companies were or will be profitable.